Cell surface GRP78: An emerging imaging marker and therapeutic target for cancer

Masoud Farshbaf1, Ahmad Yari Khosroushahi1, Solmaz Mojarad-Jabali2

  • 1Department of Medical Nanotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran; Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Insights

Targeting cell surface glucose-regulated protein 78 (csGRP78) offers a novel strategy to eradicate heterogeneous cancer cells, including resistant subpopulations. This approach holds promise for improved cancer therapy and imaging, addressing limitations of current treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cancer's heterogeneity and resistance to therapeutics necessitate novel targeting strategies.
  • Existing treatments often fail to eliminate all cancer cells, leading to recurrence and mortality.
  • Cell surface glucose-regulated protein 78 (csGRP78), overexpressed in cancer, presents a potential therapeutic and imaging target.

Purpose of the Study:

  • To review the biological roles, functional significance, and translocation mechanisms of csGRP78 in tumor cells.
  • To explore the potential of csGRP78 as a biomarker for targeted cancer therapy and imaging.
  • To outline future directions for csGRP78-targeted theranostics.

Main Methods:

  • Literature review of studies on GRP78 biology and cancer cell surface expression.
  • Analysis of GRP78's role in endoplasmic reticulum stress and cancer progression.
  • Examination of GRP78 translocation mechanisms to the cell surface.

Main Results:

  • GRP78, a heat shock protein 70 family member, functions as a molecular chaperone.
  • Cell surface GRP78 (csGRP78) is significantly overexpressed on various cancer cells and angiogenic endothelial cells.
  • csGRP78's presence facilitates targeted delivery of therapeutic and imaging agents.

Conclusions:

  • csGRP78 is a promising biomarker for developing targeted cancer therapies and diagnostic imaging agents.
  • Targeting csGRP78 can potentially overcome limitations of current cancer treatments by eradicating heterogeneous and drug-resistant cells.
  • Further research into csGRP78 targeting is crucial for advancing theranostic applications in oncology.